â??Comparison of efficacy and safety of intravenous injection of the drug ferric carboxymaltose vs iron sucrose in the treatment of iron deficiency anaemia during pregnancy â?? A randomized controlled trialâ??

â??Comparison of efficacy and safety of intravenous ferric carboxymaltose vs iron sucrose in the treatment of antepartum iron deficiency anaemia â?? A randomized controlled trialâ??

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/01/004369

Enrollment

230

Registered

2014-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- iron deficiency anaemia in pregnancy

Interventions

Intervention1: iron carboxymaltose: Required Dose is calculated using the formula : (Hb deficit x 2.4 x Wt in kg) Route of administration : IV parentral iron infusion with iron carboxymaltose 500mg

Eligibility

Inclusion criteria

Inclusion criteria: •Antepartum women whose haemoglobin is in the range of 7 to 10 gm/dl

Exclusion criteria

Exclusion criteria: • women not willing to participate • women in labor • serious medical complications • women who have a history or known allergic to parentral iron infusion

Design outcomes

Primary

Measure	Time frame
The mean rise in haemoglobin at the end of 6 weeks is an important parameter to evaluate the efficacy of the therapy.Timepoint: The mean rise in haemoglobin at the end of 6 weeks is an important parameter to evaluate the efficacy of the therapy.	—

Secondary

Measure	Time frame
To investigate the safety in terms of local and systemic reactions and tolerability of iron carboxymaltose compared with ferric sucrose.Timepoint: To investigate the safety in terms of local and systemic reactions and tolerability of iron carboxymaltose compared with ferric sucrose.	—

Countries

India

Contacts

Public ContactDr M C Metgud

JNMC , KLE University

metm@rediffmail.com9448527667

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026